Is DCB a new valid option for coronary revascularisation?

Anchorperson: R. Byrne

Discussants: M. Joner, B. Scheller, G. Stefanini, R. Waksman

Summary

This session provides an in-depth evaluation of drug-coated balloons (DCB) as a valid option for coronary revascularisation. Topics include two-year follow-up comparisons between paclitaxel and sirolimus-coated balloons, clinical outcomes after bailout stenting post-DCB angioplasty, meta-analyses contrasting DCB and DES for large native coronary artery disease, and head-to-head comparisons in treating in-stent restenosis.

Presentations available when logged in:

Paclitaxel vs sirolimus-coated balloons for CAD: 2-year follow-up of two large registries
Clinical outcomes of bailout stenting after Drug-Coated Balloon angioplasty
DEB vs DES for the treatment of large native coronary artery disease: an updated meta-analysis
Head-to-head comparison of Limus vs Paclitaxel DCBs in the Treatment of In-Stent Restenosis
Optimal Treatment for Coronary Drug-eluting Stent In-stent Restenosis

Your free My PCR account will enable you to:

Become a PCR Companion
Access slide presentations from PCR Courses
Watch session videos and LIVE cases
Discuss cases with your peers
Submit and register for PCR Courses
Register for and view PCR Webinars
Read a selection of articles in EuroIntervention
And more…

Is DCB a new valid option for coronary revascularisation?

Log in or create account for free